| pubmed-article:9500458 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9500458 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:9500458 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:9500458 | lifeskim:mentions | umls-concept:C0567416 | lld:lifeskim |
| pubmed-article:9500458 | lifeskim:mentions | umls-concept:C0021084 | lld:lifeskim |
| pubmed-article:9500458 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
| pubmed-article:9500458 | lifeskim:mentions | umls-concept:C0205410 | lld:lifeskim |
| pubmed-article:9500458 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:9500458 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9500458 | pubmed:dateCreated | 1998-3-25 | lld:pubmed |
| pubmed-article:9500458 | pubmed:abstractText | Recombinant immunotoxins have been shown to cure human tumor xenografts in mice, but their biodistribution to both tumors and normal organs has not been reported. Anti-Tac(Fv)-PE38 is a single-chain recombinant immunotoxin composed of the variable heavy and light domains of the anti-Tac monoclonal antibody that reacts with the primate interleukin 2 (IL2) receptor alpha subunit (IL2R alpha or CD25) fused to a truncated form of Pseudomonas exotoxin (PE). 125I-labeled anti-Tac(Fv)-PE38 was given i.v. to immunodeficient mice each bearing two A431 tumors, one that expresses IL2R alpha (ATAC-4) and one that does not (A431, parental). A single i.v. dose of 4 microg/mouse caused complete regression of the IL2R alpha + tumor. At 6 h, over 6% of the injected dose/g was found in the ATAC-4 tumor, and 2% was in the A431 tumor. Uptake in the ATAC-4 tumor was higher than in any other tissue. Sections of tumor examined by autoradiography indicated that anti-Tac(Fv)-PE38 was distributed throughout the entire tumor, with some portions having higher uptake than others. By subtracting uptake in tumors without receptor (A431) from uptake in receptor-containing tumors (ATAC-4), we calculated that at least 400 molecules/cell specifically bound to IL2R alpha-positive tumor cells at 90 min and 750 molecules/cell bound at 360 min. This is similar to the 400-870 molecules/cell required for >99.9% killing of ATAC-4 cells growing as a monolayer. The results show that solid tumors in mice can be eradicated like cells in tissue culture, and that delivery of less than 1000 molecules/cell is sufficient to cause complete tumor regressions. | lld:pubmed |
| pubmed-article:9500458 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9500458 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9500458 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9500458 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9500458 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:9500458 | pubmed:author | pubmed-author:PastanII | lld:pubmed |
| pubmed-article:9500458 | pubmed:author | pubmed-author:KreitmanR JRJ | lld:pubmed |
| pubmed-article:9500458 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9500458 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9500458 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:9500458 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9500458 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9500458 | pubmed:pagination | 968-75 | lld:pubmed |
| pubmed-article:9500458 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:meshHeading | pubmed-meshheading:9500458-... | lld:pubmed |
| pubmed-article:9500458 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9500458 | pubmed:articleTitle | Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. | lld:pubmed |
| pubmed-article:9500458 | pubmed:affiliation | Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. | lld:pubmed |
| pubmed-article:9500458 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9500458 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9500458 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9500458 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9500458 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9500458 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9500458 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9500458 | lld:pubmed |
